Thymosin<b>α</b>1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients

Jia, Zhi-Yang; Feng, Zihui; Tian, Rui; Wang, Qian; Wang, Linyu

doi:10.3109/08923973.2015.1069837

Cited by 13 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Th17/Treg level predicts progression of COPD and good lung function. Evidence suggests that abnormal inflammation in bronchiectasis influences the development of comorbidities in COPD, including BR [24].…”

Section: Discussionmentioning

confidence: 99%

Clinical Features of Patients with Bronchiectasis with Comorbid Chronic Obstructive Pulmonary Disease in China

et al. 2019

View full text Add to dashboard Cite

BackgroundThe prevalence of bronchiectasis with comorbid chronic obstructive pulmonary disease (COPD) is rising, which causes extremely high risk of exacerbation and mortality. We aimed to evaluate the differences in clinicopathological manifestations, immune function, and inflammation in bronchiectasis patients with comorbid COPD vs. patients who only have COPD.Material/MethodsClinicopathological characteristics, including common potentially pathogenic microorganisms, lung function, immune function, and inflammation were assessed in bronchiectasis patients with comorbid COPD and in patients who only had COPD.ResultsCompared to patients who only had COPD, patients with bronchiectasis with comorbid COPD had a higher positive rate of sputum bacteria (45.27% vs. 28.03%, P<0.01). Among them, Pseudomonas aeruginosa (P. aeruginosa) accounted for 25.19% in COPD (4.37%) (P<0.01). Likewise, patients with bronchiectasis with comorbid COPD had worse lung function, worse COPD assessment test scores, and worse Modified Medical Research Council scores. Moreover, compared with COPD only cases, patients with bronchiectasis with comorbid COPD had higher levels of white blood cells (WBC), neutrophils, C-reactive protein (CRP), and procalcitonin (PCT) (all P<0.05). Interestingly, the expression levels of Treg in patients with bronchiectasis with comorbid COPD were lower than in patients with COPD only (P<0.05). Th17 and Th17/Treg levels were higher (P<0.05). Furthermore, remarkable increased level of IL17 and IL-6 and decreased level of IL-10 and TGF-β were observed in the bronchiectasis combined COPD than in pure COPD (All P<0.05).ConclusionsOur findings suggest that P. aeruginosa is the main pathogen of bacterial infection in bronchiectasis patients with comorbid COPD. These patients have more serious clinical manifestations and immune imbalance, which should be considered when providing clinical treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Features of Patients with Bronchiectasis with Comorbid Chronic Obstructive Pulmonary Disease in China

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Based on these data, Tα1 was then used for the treatment of chronic hepatitis B and C (Iino et al, 2005;You et al, 2006), cytomegalovirus infection (Bozza et al, 2007) and invasive aspergillosis (Romani et al, 2004). In addition, the post-marketing data on Zadaxin ® (SciClone) clearly confirmed Tα1 immunomodulatory activities and related therapeutic potential also in cancer (such as Hepatocellular carcinoma, lung cancer, and melanoma), infectious diseases (sepsis, infections after bone marrow transplant, lung infections including chronic obstructive pulmonary disorder, Severe acute respiratory syndrome, and HIV) (King and Tuthill, 2016;Liu et al, 2016a;Matteucci et al, 2017;Jia et al, 2015) and improvement in immune responses of elderly immunocompromised patients (for example for enhancement of response to vaccines) (Tuthill et al, 2012).…”

Section: Thymosins: the Old And The Newmentioning

confidence: 92%

Thymosins in multiple sclerosis and its experimental models: moving from basic to clinical application

Severa

Zhang

Giacomini

et al. 2019

Multiple Sclerosis and Related Disorders

View full text Add to dashboard Cite

“…It is also in late-stage clinical testing in the USA and Europe for hepatitis C and melanoma. There are novel applications and other completed trials in a number of diseases and disorders, including septic shock, acute respiratory distress syndrome, peritonitis, acute cytomegalovirus infection, TB, severe acute respiratory syndrome, and lung infections in critically ill patients [38][39][40][41][42][43][44][45][46][47][48][49]. The spectrum of diseases in which Ta1 treatment can be of benefit is constantly increasing, as attested by the very recent findings on multiple sclerosis and cystic fibrosis [67,68].…”

Section: The Ta1 Clinical Historymentioning

confidence: 99%

“…Currently, Ta1 is included in the treatment of several diseases associated with immune dysfunction, based just on its own ability to target different cell types [38][39][40][41][42][43][44][45][46][47][48][49].…”

Section: Introductionmentioning

confidence: 99%

Serum thymosin alpha 1 levels in normal and pathological conditions

Pica

Gaziano

Casalinuovo

et al. 2018

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Thymosin alpha 1 (Ta1) is a natural occurring peptide hormone that is crucial for the maintenance of the organism homeostasis. It has been chemically synthesized and used in diseases where the immune system is hindered or malfunctioning. Areas covered: Many clinical trials investigate the Ta1 effects in patients with cancer, infectious diseases and as a vaccine enhancer. The number of diseases that could benefit from Ta1 treatment is increasing. To date, questions remain about the physiological basal levels of Ta1 and the most effective dose and schedule of treatment. Evidence is growing that diseases characterized by deregulation of immune and/or inflammatory responses are associated with serum levels of Ta1 significantly lower than those of healthy individuals: to date, B hepatitis, psoriatic arthritis, multiple sclerosis and sepsis. The sputum of cystic fibrosis patients contains lower levels of Ta1 than healthy controls. These data are consistent with the role of Ta1 as a regulator of immunity, tolerance and inflammation. Expert opinion: Low serum Ta1 levels are predictive and/or associated with different pathological conditions. In case of Ta1 treatment, it is crucial to know the patient's baseline serum Ta1 level to establish effective treatment protocols and monitor their effectiveness over time.

show abstract

Thymosinα1 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients

Abstract: Tα1 plus routine treatment could improve the immune function of AECOPD patients and inhibit the inflammatory reaction, thus reducing the recurrence of chronic obstructive pulmonary disease (COPD).

Cited by 13 publications

References 12 publications

Clinical Features of Patients with Bronchiectasis with Comorbid Chronic Obstructive Pulmonary Disease in China

Clinical Features of Patients with Bronchiectasis with Comorbid Chronic Obstructive Pulmonary Disease in China

Thymosins in multiple sclerosis and its experimental models: moving from basic to clinical application

Serum thymosin alpha 1 levels in normal and pathological conditions

Contact Info

Product

Resources

About